Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (6): 48-53.doi: 10.6040/j.issn.1671-7554.0.2024.0267

• Clinical Medicine • Previous Articles    

The predictive value of systemic immune-inflammation index for immune checkpoint inhibitor treatment-related adverse reactions in patients with primary liver cancer

TIAN Lijun1, SANG Yujie1, SUN Yujing1, HAN Bing1, QIN Chengyong2, QI Jianni3   

  1. 1. Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China;
    2. Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China;
    3. Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
  • Published:2024-07-15

PDF (PC)

81

Key words: Systemic immuneinflammation index, Primary liver cancer, Immune checkpoint inhibitors, Tmmnerelated adverse events

CLC Number: 

  • R735.7
[1] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.
[2] Liu Y, Zheng JX, Hao JL, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019[J]. Cancer Med, 2022, 11(5): 1310-1323.
[3] Zheng YM, Wang SW, Cai JB, et al. The progress of immune checkpoint therapy in primary liver cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188638.
[4] Darnell EP, Mooradian MJ, Baruch EN, et al. Immune-related adverse events(irAEs): diagnosis, management, and clinical pearls[J]. Curr Oncol Rep, 2020, 22(4): 39.
[5] Wang E, Kraehenbuehl L, Ketosugbo K, et al. Immune-related cutaneous adverse events due to checkpoint inhibitors[J]. Ann Allergy Asthma Immunol, 2021, 126(6): 613-622.
[6] Xie RJ, Liu XZ, Wu HY, et al. Associations between systemic immune-inflammation index and abdominal aortic calcification: results of a nationwide survey[J]. Nutr Metab Cardiovasc Dis, 2023, 33(7): 1437-1443.
[7] Tian BW, Yang YF, Yang CC, et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis[J]. Immunotherapy, 2022, 14(18): 1481-1496.
[8] Nakamoto S, Ohtani Y, Sakamoto I, et al. Systemic immune-inflammation index predicts tumor recurrence after radical resection for colorectal cancer[J]. Tohoku J Exp Med, 2023, 261(3): 229-238.
[9] 施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. SHI Guoming, HUANG Xiaoyong, REN Zhenggang, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors(2021 edition)[J]. Chinese Journal of Digestive Surgery, 2021, 20(12): 1241-1258.
[10] Geraghty JR, Lung TJ, Hirsch Y, et al. Systemic immune-inflammation index predicts delayed cerebral vasospasm after aneurysmal subarachnoid hemorrhage[J]. Neurosurgery, 2021, 89(6): 1071-1079.
[11] Muntyanu A, Netchiporouk E, Gerstein W, et al. Cutaneous Immune-Related Adverse Events(irAEs)to Immune Checkpoint Inhibitors: a Dermatology Perspective on Management[J]. J Cutan Med Surg, 2021, 25(1): 59-76.
[12] Ramos-Casals M, Flores-Chávez A, Brito-Zerón P, et al. Immune-related adverse events of cancer immunotherapies targeting kinases[J]. Pharmacol Ther, 2022, 237: 108250. doi:10.1016/j.pharmthera.2022.108250.
[13] Zou R, Hao YH, Wang YY, et al. A multicenter retrospective analysis: factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer[J]. Cancer Rep, 2024, 7(2): e1918. doi:10.1002/cnr2.1918.
[14] 乔师师, 郭化虎, 杨振, 等. 晚期肝细胞癌免疫治疗的相关不良反应[J]. 广东医学, 2023, 44(3): 369-373. QIAO Shishi, GUO Huahu, YANG Zhen, et al. Adverse reactions related to immunotherapy for advanced hepatocellular carcinoma[J]. Guangdong Medical Journal, 2023, 44(3): 369-373.
[15] Faak F, Buni M, Falohun A, et al. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events[J]. J Immunother Cancer, 2023, 11(6): e006814. doi:10.1136/jitc-2023-006814.
[16] Ke WH, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer(NSCLC)with immune-related adverse events(irAEs)[J]. Thorac Cancer, 2020, 11(4): 835-839.
[17] 王汉萍. 肝癌免疫检查点抑制剂治疗相关不良反应及处理[J]. 临床肝胆病杂志, 2022, 38(5): 985-991. WANG Hanping. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. Journal of Clinical Hepatology, 2022, 38(5): 985-991.
[18] Dimitriou F, Hogan S, Menzies AM, et al. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy[J]. Eur J Cancer, 2021, 157: 214-224. doi:10.1016/j.ejca.2021.08.031.
[19] Li J, Shi HY, Zhou M. Correlation between preoperative systemic immune inflammation index, nutritional risk index, and prognosis of radical resection of liver cancer[J]. World J Gastrointest Surg, 2023, 15(11): 2445-2455.
[20] Zhao EF, Cheng YP, Yu CX, et al. The systemic immune-inflammation index was non-linear associated with all-cause mortality in individuals with nonalcoholic fatty liver disease[J]. Ann Med, 2023, 55(1): 2197652.
[21] Polk N, Budai B, Hitre E, et al. High neutrophil-to-lymphocyte ratio(NLR)and systemic immune-inflammation index(SII)are markers of longer survival after metastasectomy of patients with liver-only metastasis of rectal cancer[J]. Pathol Oncol Res, 2022, 28: 1610315. doi:10.3389/pore.2022.1610315.
[22] Wang D, Hu X, Xiao L, et al. Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC[J]. J Gastrointest Surg, 2021, 25(2): 421-427.
[23] Jomrich G, Paireder M, Kristo I, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma[J]. Ann Surg, 2021, 273(3): 532-541.
[24] Liu JJ, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964. doi:10.1002/jcla.22964.
[25] Anpalakhan S, Huddar P, Behrouzi R, et al. Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis[J]. Front Oncol, 2023, 13: 1163768. doi:10.3389/fonc.2023.1163768.
[1] LI Bo, LIU Jingfang, BAO Jinpeng, LI Xiangze, QIN Guangyang, TIAN Hu. Application value of three-dimensional visualization combined with indocyanine green fluorescence technique in laparoscopic hepatectomy in the treatment of 51 patients with primary liver cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 83-88.
[2] YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.
[3] XU Xiao-mei1, YU Jiao1, LI Guo-hua1, JIANG Yan2, JIANG Zhao-quan3, ZHANG Ping3, CHENG Xiao-yun1. Clinical research on treatment of liver decompensation of primary
liver cancer by the method of Yiqibushenquyu [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(12): 70-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd